Katherine Dam Email & Phone Number

Belgium

United States

1 of 4 FRMs to support launches - biosimilar Yuflyma. Worked with virtual sales team, immunology sales team, and oncology sales team for launch of SC infliximab Zymfentra and support biosimilar Vegzelma. Developed field strategy for Optum initiative for VSS & FRM collaboration. Worked with NADs and SPs to optimize payer wins.

West Region

1 of 4 FRMs who supported for CIMERLI (biosimilar) launch. Oncology UDENYCA auto injector launch.

Southern California

2022 YTD (Aug)• # 1/36 in the nation for APPROVED attainment• # 2/36 in the nation for ACCESS attainment• #1/10 in the region for all metrics• Only ARM in the region to exceed over 100% for all metrics for 2 years in a row• PAID – 117%, APPROVED – 112%, ACCESS – 110%• Q1 Top 2/36 in lowest withdrawal rate: San Diego: 7%, Region 20%, Nation 17%• National advisory board for reimbursement and sales collaboration2021 Rookie of the Year• Only ARM in the… Show more 2022 YTD (Aug)• # 1/36 in the nation for APPROVED attainment• # 2/36 in the nation for ACCESS attainment• #1/10 in the region for all metrics• Only ARM in the region to exceed over 100% for all metrics for 2 years in a row• PAID – 117%, APPROVED – 112%, ACCESS – 110%• Q1 Top 2/36 in lowest withdrawal rate: San Diego: 7%, Region 20%, Nation 17%• National advisory board for reimbursement and sales collaboration2021 Rookie of the Year• Only ARM in the region to achieve 100% for all metrics for the year• Ranked top 2 of 10 for PAID cases: San Diego 101%. Exceeded paid shipped rate goal of 63%San Diego: 64%, Region: 52%, Nation: 57%• Ranked top 2 of 10 for APPROVED cases: San Diego 103%. Exceeded territory approval rate goal of 74% San Diego: 76%, Region: 64%, Nation: 68%• Ranked top 3 of 10 for ACCESS cases: San Diego 100%. Achievement territory access goal of 85%San Diego: 85%, Region: 78%, Nation: 79%• Improved withdrawal rate goal 17%. San Diego: 14%, Region: 22%, Nation: 19%• Improved baseline for San Diego territory from 2020 to 2021.Approval rate; 66% to 75%, Paid ship rate: 57% to 62%Withdrawal rate: 21% to 14% Show less

Regional trainer. Therapeutics in Rheumatology, Neurology, Nephrology, Pulmonology and Ophthalmology. Promote Acthar in 7 disease states in rheumatology. Grew territory volume and baseline goal by an average of 60% compared to national or regional decline from between 2017-2020. Ranked #5/65 in the nation and won President’s Club in 2019. Currently ranked #2 in volume for the region and top 28% nationally on vial leaderboard.

Launched Corlanor and Repatha in the Cardiovascular market. Ranked #38 of 243 reps in the nation for first semester in 2017.

My responsibility included exceeding sales goal. Launched first biologic into Primary Care in June 2010. Exceeded goals 4 of 5 years. Ranked top 10%, 3 of the 5 years. Won 2 Chairman Circles and 4 National Team Excellence awards. Experienced with buy & bill, brown bag, reimbursements and setting up injection networks.

Won Challenge of the Champion. My responsibility included growing market share of all brands. Boniva, Bovina Injection and Tamuflu. Set up infusion network to improve patient access points.

My responsibility included promotion is Actonel, Tazorac and Asacol. Ranked #1 in the nation for sales goal attainment for 2005. Achieved highest national market share gain for Asacol for 2005.

My responsibility included promoting Riomet and OTC (Benadryl, Bayer Asprin and Pedicare).

Aliso Viejo, California, United States

Collaborated with cross functional internal teams and external teams of engineers in to build power plants. Conducted classroom training and rolled out customized electronic Request for Purchase data sheets to engineers. Conducted field visit to train on-site staff. Responsible for PID updates and sizing of control valves for power plants. Selected as chairman for National Engineering Week.